Global fish vaccine market is estimated to be valued at USD 375.1 million in 2024 and is expected to reach USD 691.2 million by 2031, exhibiting a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031.
<
Figure 1. Fish Vaccine Market Share (%), By Region, 2024
![Fish Vaccine Market - IMG1](/sample/img/COH1508778-f1.webp)
Global fish vaccine market has witnessed steady growth in the past few years, owing to rise in aquaculture industry and increasing prevalence of deadly fish diseases. Fish vaccines help prevent fish populations from infectious diseases, thus, avoiding heavy economic losses to fish farmers and traders. Vaccines aid immunization of fish species that are raised through aquaculture practices for both food and ornamental purposes. Growing consumption of seafood along with rising demand for sustainable fish farming can boost demand for fish vaccines globally in the near future.
Market Dynamics:
Increasing adoption of aquaculture practices due to rising global seafood demand can drive the fish vaccine market growth. Increasing prevalence of various viral and bacterial infections such as Vibriosis and Epitheliocystis disease particularly among salmon species farmed in Europe and North America can boost sales of fish vaccines. However, high costs associated with fish vaccine R&D and stringent regulations pertaining to launch of new fish vaccines can hamper the market growth. Meanwhile, introduction of novel adjuvant technologies for developing efficient thermostable fish vaccines can provide lucrative business opportunities for manufacturers in the industry.
Key Features of the Study:
- This report provides in-depth analysis of the global fish vaccine market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global fish vaccine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Zoetis, Merck & Co., Inc., Phibro Animal Health Corporation, Virbac, Hipra, Veterquimica S.A., Tecnovax, Anthropic, HIPRA
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global fish vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fish vaccine market
Detailed Segmentation-
- By Vaccine Type:
- Killed Vaccine
- Inactivated Vaccine
- Attenuated Vaccine
- Toxoid Vaccine
- Subunit Vaccine
- Conjugate Vaccine
- Recombinant Vector Vaccines
- By Indication:
- Furunculosis
- Vibriosis
- Yersiniosis
- Enteric septicaemia
- Others
- By Route of Administration:
- Injection
- Immersion
- Spray
- Oral
- Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Merck Animal Health (MSD Animal Health)
- Zoetis
- Elanco
- Virbac
- HIPRA
- Veterquimica S.A.
- Tecnovax
- Phibro Animal Health Corporation
- Ridgeway Biologicals Ltd.
- Nisseiken Co., Ltd.
- Aquatic Animal Health Ltd
- Ictyogroup
- Benchmark Holdings plc
- Vaxxinova
- Alpha Biotech Ltd.
- Vallee S.A.
- Ringpu Biology
- Nippon Zenyaku Kogyo Co., Ltd.
- Chengdu Tech-bank Biological Products
- Weiyuan Gene Tech